• Latest Posts

FDA clears SparingVision’s investigational new drug application to treat ocular diseases

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

SparingVision raises €75M for genomic medicines for ocular diseases

Improved vision with less eye injections for patients after primary endpoints met in trials

Opthea secures up to $170M in financing for wet AMD treatment

Full label approval given by FDA for eye disease drug, CIMERLI


Finnish and US companies form exclusive agreement for development of sustained release drug